Union Ministry of Health and Family Welfare Prohibits Manufacture, Sale and Distribution of 16 Fixed Dose Combinations (FDCs) in Public Interest

1. At a Glance

Union Ministry of Health and Family Welfare (MoHFW) issued gazette notifications on 20 June 2026 banning manufacture, sale and distribution of 16 FDCs for human use with immediate effect, invoking Section 26A of the Drugs and Cosmetics Act, 1940 [S1].
Action follows a Supreme Court-mandated comprehensive review of FDCs sold in India, executed through the Drugs Technical Advisory Board (DTAB) [S1][S2].
Important for UPSC because it ties together drug regulation architecture (CDSCO, DTAB, DCGI), Centre-State legislative split on drugs (Concurrent List Entry 19), rational drug use, and judicial intervention in public health.

2. Why in the News

20 June 2026: MoHFW notified prohibition of 16 FDCs in public interest; said decision aims to ensure availability of only scientifically justified drug combinations [S1].
Continues a recent regulatory wave: August 2024 ban on 156 FDCs (allergy, multivitamin, anti-parasitic, hair-growth, painkiller, antibiotic combinations) [S3].

3. Background & Evolution

Fixed Dose Combination (FDC): a single dosage form containing two or more active pharmaceutical ingredients (APIs) in fixed ratio — permitted only if combination is therapeutically rational and safer/more efficacious than the components alone (WHO essential medicines principle).
2007–2012: State licensing authorities approved hundreds of FDCs without Central (CDSCO) approval — flagged by Parliamentary Standing Committee (59th Report, 2012).
Kokate Committee (2014), chaired by Prof. C.K. Kokate, reviewed ~6,300 FDCs marketed without DCGI approval [S4].
March 2016: Centre banned 344 FDCs; manufacturers (Pfizer, others) moved Delhi HC; Delhi HC quashed ban (Dec 2016).
Supreme Court judgment, 15 December 2017: directed DTAB to re-examine the FDCs [S2].
7 September 2018: MoHFW prohibited 328 FDCs and restricted 6 FDCs based on DTAB's finding of "no therapeutic justification" and "risk to human beings" [S2].
June 2023: 14 FDCs (cough/fever) banned. August 2024: 156 FDCs banned [S3].
June 2026: 16 more FDCs prohibited [S1].

4. Core Static Facts

Statutory base: Section 26A, Drugs and Cosmetics Act, 1940 — empowers Central Government to prohibit manufacture, sale, distribution of any drug in public interest [S1][S2].
Expert body: Drugs Technical Advisory Board (DTAB) — constituted under Section 5 of the Act; highest statutory body advising Centre/States on technical drug matters [S2].
Regulator: Central Drugs Standard Control Organisation (CDSCO) under MoHFW, headed by Drugs Controller General of India (DCGI).
List: Concurrent List Entry 19 ("Drugs and poisons") — Centre legislates, States license/enforce.
Notification instrument: Gazette of India notifications under Sec 26A; immediate effect [S1].
Recent quanta: 328 FDCs (2018), 14 (2023), 156 (Aug 2024), 16 (Jun 2026) [S1][S2][S3].

5. Multi-Dimensional Analysis

Legal / Constitutional - Section 26A invoked; precedent set in Pfizer Ltd. v. Union of India (2018) SC — upheld Centre's power if DTAB review is followed (cured the procedural lapse identified by Delhi HC in 2016) [S2]. - Drug regulation sits on Concurrent List → tension between Central CDSCO approvals and State Drug Controllers' licensing.

Scientific / Public Health - Irrational FDCs cause antimicrobial resistance (AMR), masked diagnoses, adverse drug reactions, and dose-escalation toxicity. - WHO criteria: FDC must demonstrate synergy, improved compliance, or reduced ADR versus single agents [S2].

Administrative / Governance - Recurring loophole: State licensing of unapproved FDCs without prior CDSCO clearance (highlighted by 59th Parliamentary Standing Committee Report, 2012). - Implementation gap: enforcement requires States to withdraw existing stock, recall, and prosecute — uneven across States.

Economic - Indian pharmaceutical FDC market is one of the world's largest by volume; bans affect listed and MSME formulators. - Push for rational prescribing dovetails with Jan Aushadhi generic-medicine strategy.

Ethical - Patient-safety primacy vs. industry/livelihood interest; consent and information asymmetry where doctors prescribe irrational combinations.

6. Recent Developments (last 12-18 months)

20 June 2026: 16 FDCs prohibited under Sec 26A [S1].
August 2024: 156 FDCs banned (antibiotics, painkillers, multivitamins) [S3].
Continuing DTAB review of legacy FDCs flagged by Kokate Committee.

7. Prelims Hooks

Section 26A, Drugs and Cosmetics Act, 1940 — enables prohibition in public interest [S1].
DTAB constituted under Section 5 of the Drugs and Cosmetics Act, 1940 [S2].
CDSCO is the apex national regulator; head is DCGI — under MoHFW (NOT Ministry of Chemicals & Fertilizers).
Kokate Committee (2014) reviewed FDCs [S4 contextual].
Supreme Court direction date: 15 December 2017 in the FDC matter [S2].
2018 ban: 328 FDCs prohibited + 6 restricted by gazette of 7 September 2018 [S2].
August 2024: 156 FDCs banned [S3].
June 2026: 16 FDCs banned, MoHFW [S1].
"Drugs and poisons" is Entry 19 of the Concurrent List (Seventh Schedule).
Pfizer v. Union of India (2018) — SC upheld Centre's FDC ban power.
FDC = two or more APIs in a single dosage form in fixed ratio.

8. Mains Relevance

GS-II: Government policies & interventions for development in social sectors (Health); role of regulatory bodies; judicial activism in public health.
GS-III: Issues relating to intellectual property, pharma sector, drug regulation, AMR; Science & Tech — indigenous drug development.
GS-IV: Ethics of dual-use industry; conflict of interest between profit and public health.

Question stems - "Irrational fixed-dose combinations remain a persistent regulatory blind spot in India. Examine the institutional framework and suggest reforms." (GS-II, 250 words) - "Discuss the role of the Drugs Technical Advisory Board (DTAB) and the Supreme Court in reshaping India's FDC regulation since 2016." (GS-II, 150 words) - "Antimicrobial resistance in India is exacerbated by irrational fixed-dose antibiotic combinations. Critically analyse." (GS-III, 250 words)

9. Related Topics to Study Next

CDSCO & DCGI — apex drug regulator architecture.
Drugs and Cosmetics Act, 1940 & Rules, 1945 — pillar statute; proposed Drugs, Medical Devices and Cosmetics Bill to replace it.
Jan Aushadhi (PMBJP) — affordability flank to rational-use agenda.
National Pharmaceutical Pricing Authority (NPPA) — price control under DPCO 2013.
National Action Plan on AMR (2017) — directly affected by FDC antibiotic misuse.
WHO Model List of Essential Medicines vs National List of Essential Medicines (NLEM 2022).
Parliamentary Standing Committee 59th Report (2012) — origin of FDC scrutiny.
Schedules of the Drugs and Cosmetics Act (Sch H, H1, X).

10. Common Errors / Trap Areas

Confusing DTAB (technical) with DCC (Drugs Consultative Committee — coordination); both under the Act but different roles.
Attributing drug regulation to Department of Pharmaceuticals (under Ministry of Chemicals & Fertilizers) — wrong; CDSCO is under MoHFW (DoP handles pricing/industry policy, NPPA, Jan Aushadhi).
Citing Section 26B (which deals with shortages) instead of Section 26A (public-interest prohibition).
Mixing up 2016 ban (344 FDCs, quashed) with 2018 ban (328 FDCs, upheld).
Treating FDCs as banned outright — only irrational/unjustified FDCs are banned; many essential FDCs (e.g., anti-TB, ART) are WHO-recommended.

11. Sources

[S1] Union Ministry of Health and Family Welfare Prohibits Manufacture, Sale and Distribution of 16 Fixed Dose Combinations (FDCs) in Public Interest — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2275595 — (tier 1)
[S2] Prohibition and restriction of manufacture, sale and distribution of Fixed Dose Combinations (FDCs) — https://www.pib.gov.in/Pressreleaseshare.aspx?PRID=1545741 — (tier 1)
[S3] Banning of FDC Drugs (PIB) — https://pib.gov.in/newsite/PrintRelease.aspx?relid=142184 — (tier 1)
[S4] Banned Medicines (PIB) — https://www.pib.gov.in/newsite/PrintRelease.aspx?relid=70841 — (tier 1)